India’s first dedicated autoimmune diagnostics lab, IMMUCARE, launched in KeralaJune 20, 2019
IMMUCARE, a research-oriented diagnostics laboratory dedicated for supporting the medical fraternity and patients suffering from all types of autoimmune diseases, has been launched in Kerala. This new generation lab, located in Kochi, is first of its kind in India. A novel concept in the field of diagnostics, IMMUCARE perfectly blends high-end technology with strong expertise of experienced clinicians, pathologists and scientists to address the unmet needs of diagnosing autoimmune disorders, a complex health condition, which is on a rise in the country.
Launched by Kerala’s most reputed rheumatologist Dr Padmanabha Shenoy and well known science entrepreneur Sam Santhosh, Founder & Chairman, MedGenome Inc, a global leader in personalised medicine with unique genomic solutions, along with Dr Aparna Jairam, India’s leading pathologist and a diagnostics industry veteran, the new venture is positioned as a referral lab catering to the need of diagnostic labs, hospitals and doctors across the country. It is also being positioned as a Centre of Excellence with its strong focus on research in the area of autoimmune diseases.
IMMUCARE, a joint venture between Dr Shenoy-led Care Hospital and MedGenome, aims at providing accurate, precise and timely diagnostic analysis and prognostic information to clinicians and patients and thereby help and support the community from the adverse effect of autoimmune and associated ailments.
“With the soft launch of IMMUCARE labs, a dream project is taking shape. A centre of excellence, where all the tests to diagnose and treat autoimmune diseases available under one roof, it was a dream that we have been working on for more than a year,” said Dr Shenoy, Director, IMMUCARE, while launching the website of the new lab.
He added that; “State of the art-technology to perform cell based assays, genetic tests and autoantibody detection combined with a well experienced and committed team of professionals make this venture unique. Our aim is to help all doctors including rheumatologists, neurologists, nephrologists, gastroenterologists and dermatologists to deal with autoimmune diseases better.”
Commenting on IMMUCARE vision, Dr Aparma Jairam, Chief Executive Officer, said, “We have a very strong focus on hiring and retaining qualified experienced manpower to drive our different departments within and outside the labs. We believe in understanding the requirements and challenges faced by medical fraternity while addressing the area of autoimmune diseases.”
“Despite our size, we are keen to maintain an environment that nurtures some of the top thinkers in India in their respective fields of expertise. To support us on this venture , we have a team of medical advisors who are the experts in their respective domains,” she said adding that; “We are passionate about developing innovative, ground-breaking tests, products and tools to enhance patient care, provide value to our clients, and transform information into knowledge and insights.”
Mostly known autoimmune diseases in India at present include certain types of thyroid diseases—Grave’s and Hashimoto’s, inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis, and skin diseases such as psoriasis and vitiligo. There is also a growing number of women at reproductive age being diagnosed with autoimmune diseases such as lupus and APS, adversely affecting fertility and in some cases also lead to miscarriage, foetal death and premature birth.The disease starts when the body’s immune cells, which are supposed to fight invading germs and toxins, turn against one’s own cells. It can affects almost all organs in the body and more often multiple organs. Global estimate shows that nearly 700 million people currently suffer from some kind of an autoimmune disease, stages ranging from mild, moderate and severe. These disorders were not given adequate attention in India in the past mainly due to lack awareness and a general impression that they were untreatable.